Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Curcumin  COVID-19 treatment studies for Curcumin  C19 studies: Curcumin  Curcumin   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Improvement in SpO2 -46% Improvement Relative Risk c19early.org/t Hassaniazad et al. Curcumin for COVID-19 RCT LATE Is late treatment with curcumin beneficial for COVID-19? Double-blind RCT 40 patients in Iran No significant difference in recovery Hassaniazad et al., Phytotherapy Research, doi:10.1002/ptr.7294 Favors curcumin Favors control
A triple-blind, placebo-controlled, randomized clinical trial to evaluate the effect of curcumin-containing nanomicelles on cellular immune responses subtypes and clinical outcome in COVID-19 patients
Hassaniazad et al., Phytotherapy Research, doi:10.1002/ptr.7294
Hassaniazad et al., A triple-blind, placebo-controlled, randomized clinical trial to evaluate the effect of curcumin-containing.., Phytotherapy Research, doi:10.1002/ptr.7294
Sep 2021   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Small RCT with 40 low risk patients in Iran, 20 treated with nano-curcumin, showing no significant difference in outcomes with treatment. Authors note that treatment can improve peripheral blood inflammatory indices and modulate immune response by decreasing Th1 and Th17 responses, increasing T regulatory responses, further reducing IL-17 and IFN-γ, and increasing suppressive cytokines TGF-β and IL-4.
relative improvement in SpO2, 45.7% worse, RR 1.46, p = 0.90, treatment 20, control 20.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Hassaniazad et al., 19 Sep 2021, Double Blind Randomized Controlled Trial, placebo-controlled, Iran, peer-reviewed, 12 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperCurcuminAll
Abstract: Received: 7 March 2021 Revised: 2 September 2021 Accepted: 4 September 2021 DOI: 10.1002/ptr.7294 RESEARCH ARTICLE A triple-blind, placebo-controlled, randomized clinical trial to evaluate the effect of curcumin-containing nanomicelles on cellular immune responses subtypes and clinical outcome in COVID-19 patients Mehdi Hassaniazad1 | Ebrahim Eftekhar2 | Behnaz Rahnama Inchehsablagh3,4 | Hossein Kamali3 | Abdolali Tousi3 | Mahmoud Reza Jaafari5,6,7 | Milad Rafat3 | Mohammad Fathalipour8 | Sara Nikoofal-Sahlabadi9 | Hesam Alizade1 | Amin Reza Nikpoor10 Hamed Gouklani1 | 1 Infectious and Tropical Diseases Research Center, Hormozgan Health Institute, Hormozgan University of Medical Sciences, Bandar Abbas, Iran 2 Endocrinology and Metabolism Research Center, Hormozgan University of Medical Sciences, Bandar Abbas, Iran 3 Student Research Committee, Faculty of Medicine, Hormozgan University of Medical Sciences, Bandar Abbas, Iran 4 Department of Physiology, Faculty of Medicine, Hormozgan University of Medical Sciences, Bandar Abbas, Iran 5 Nanotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran 6 Department of Pharmaceutical Nanotechnology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran 7 Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran 8 Department of Pharmacology and Toxicology, Faculty of Pharmacy, Hormozgan University of Medical Sciences, Bandar Abbas, Iran 9 Department of Pharmaceutics, Faculty of Pharmacy, Hormozgan University of Medical Sciences, Bandar Abbas, Iran 10 Molecular Medicine Research Center, Hormozgan Health Institute, Hormozgan University of Medical Sciences, Bandar Abbas, Iran Correspondence Amin Reza Nikpoor, Molecular Medicine Research Center, Hormozgan Health Institute, Hormozgan University of Medical Sciences, Bandar Abbas, Iran. Email: nikpoora@hums.ac.ir; nikpoora@ gmail.com In COVID-19 patients, cytokine storm due to excessive immune responses can cause severe complications. In this study, we investigated the effect of curcumin nanomicelles on clinical outcome and cellular immune responses subtypes changes in COVID-19 patients. A randomized, triple-blinded, placebo-controlled study was done. Forty COVID-19 patients were included into two groups of nano-curcumin and pla- Funding information The financial supports of Hormozgan University of Medical Sciences, Bandar Abbas, Iran (grant no. 990126) is acknowledged. The Exir Nano Sina company had no role in funding or dedication of SinaCurcumin and placebo capsules, data collection, analysis, and interpretation of data. cebo. The nano-curcumin group received 40 mg of nano-curcumin capsule, four times per day for 2 weeks. Clinical signs and gene expression of TBX21, GATA3, RORC and FOXP3 genes and IFN-γ, IL-4, IL-17 and TGF-β cytokines serum levels were measured at time points of 0, 7 and 14 days. Serum levels of IFN-γ (p = .52) and IL-17 (p = .11) decreased, while IL-4 (p = .12) and TGF-β (p = .14) increased in the nanocurcumin group compared with placebo on day 14. Moreover, gene expressions of TBX21 (p = .02) and FOXP3 (p = .005) genes were significantly decreased and increased between nano-curcumin and placebo groups on day 7, respectively. It can be concluded that administration of nano-curcumin in inflammatory phase of COVID19 can accelerate recovering of the acute..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit